Drug intelligence / Profile preview

AT-020

Development stage: Preclinical
Lead developer: Asieris Pharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AT-020 is an antibody-drug conjugate (ADC) being developed by Asieris Pharmaceuticals for the treatment of solid tumors. The drug utilizes ADC technology, which typically involves an antibody linked to a cytotoxic agent, allowing targeted delivery of the therapeutic payload directly to cancer cells while minimizing effects on normal tissues. As of mid-2024, AT-020 remains in preclinical development and has not yet entered clinical trials[1][2].

Beyond the preview

Go deeper on AT-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-020.

Explore the full profile